Research · BPC-157 cluster

BPC-157 dosing research protocols & reconstitution

Wellness Labs Editorial··8 min read
Medically reviewed by
Wellness Labs Research Team · Research and Editorial
Last reviewed

“What dose?” is the most-asked BPC-157 question and the one most often answered badly online — with confident human protocols that the published literature does not support. This spoke does the honest version: it reports the doses and routes the actual preclinical studies used, walks through the reconstitution diluent question that is genuinely specific to BPC-157, and shows the syringe math. It is a research-protocol reference, not a human dosing recommendation.

The doses the published studies actually used

Because BPC-157 research is preclinical, the doses are reported per kilogram of rodent body weight — not as a human milligram dose. A representative, well-documented regimen comes from Japjec and colleagues (2021, Biomedicines), who used 10 µg/kg and 10 ng/kg given intraperitoneally, or per-orally in drinking water at roughly 0.16 µg/mL, continued from surgery through to sacrifice at 7–42 days [1]. The striking feature of the BPC-157 literature is that the µg/kg and ng/kg arms — a thousand-fold apart — both produced effects, which is unusual and one reason the dose-response relationship is considered poorly resolved.

The honest headline: the published doses are rodent µg/kg figures, and the same studies often show effects across a 1,000-fold dose range. Any single “human dose” quoted with confidence online is an extrapolation the literature does not actually license.

Administration routes in the literature

The reviews consistently report three routes used across models: intraperitoneal injection (the most common in rodent work), per-oral administration (in drinking water), and local application at the injury site. Gwyer and colleagues (2019, Cell and Tissue Research) survey the musculoskeletal soft-tissue literature where these routes recur [2], and the Seiwerth 2021 wound-repair review documents the same route diversity across the broader record [3]. The notable point for a research reader is that per-oral activity is reported at all — many peptides are not orally active, and BPC-157’s reported per-oral effect is part of why it draws interest.

Reconstitution: the acetic-acid-water question

BPC-157 is the peptide most associated with an acidic reconstitution diluent. While most research peptides are reconstituted with bacteriostatic water, published storage considerations favour a low-pH diluent (0.6% acetic acid water, ~pH 3) for BPC-157 when a protocol extends beyond a week or two, because the peptide is reported to degrade faster at the neutral pH of bacteriostatic water. Bacteriostatic water is workable for short single-use windows; acetic acid water is the preferred choice for multi-week protocols. The full diluent rationale is in our acetic acid water guide.

Related reading in the BPC-157 cluster

For how BPC-157 is proposed to act, see BPC-157 mechanism research. For the gastrointestinal evidence where many of these protocols were run, see BPC-157 gut research. For the diluent choice in depth, see acetic acid water and the general reconstitution & CoA guide. Overview: BPC-157 synopsis · research peptides in the UAE.

Further reading

Peer-reviewed citations used inline:

Last reviewed 11 June 2026. Wellness Labs supplies BPC-157 as research-grade lyophilised powder for non-clinical investigation. Editorial inbox: info@uaewellnesslab.com.

Frequently asked questions

What dose of BPC-157 is used in research?
Published BPC-157 studies are rodent studies, so doses are reported per body weight, not as a human dose. A representative documented regimen used 10 µg/kg and 10 ng/kg given intraperitoneally, or per-orally in drinking water at roughly 0.16 µg/mL, continued over days to weeks. A notable feature is that effects are reported across a roughly thousand-fold dose range, which is why the dose-response relationship is considered poorly resolved. There is no validated human dose.
How do you reconstitute BPC-157?
BPC-157 ships as a lyophilised powder and is reconstituted with a diluent for research use. A 5 mg vial reconstituted with 2 mL yields 2.5 mg/mL; with 3 mL it yields about 1.67 mg/mL. Inject the diluent slowly down the inside wall of the vial — never directly onto the powder — and swirl gently rather than shaking. A free reconstitution calculator handles any vial-size, concentration and dose-volume combination.
Should BPC-157 use acetic acid water or bacteriostatic water?
BPC-157 is the peptide most associated with an acidic diluent. Published storage considerations favour 0.6% acetic acid water (around pH 3) over neutral-pH bacteriostatic water for protocols extending beyond a week or two, because BPC-157 is reported to degrade faster at neutral pH. Bacteriostatic water is workable for short single-use windows; acetic acid water is preferred for multi-week research protocols. This acidic-diluent preference is fairly specific to BPC-157.
What routes of administration are used for BPC-157?
The reviews consistently report three routes across rodent models: intraperitoneal injection (most common), per-oral administration in drinking water, and local application at the injury site. The reported per-oral activity is notable because many peptides are not orally active — it is one of the features that draws research interest to BPC-157. All route data is from preclinical animal studies.
Is there a recommended human BPC-157 dose?
No. There is no validated human dose for BPC-157. Human dose figures circulating online are extrapolations from rodent µg/kg data, not conclusions from human trials, and the same studies often show effects across a thousand-fold dose range. BPC-157 is not an approved medicine in any major jurisdiction; the dose figures in the research literature are protocol reference values for non-clinical investigation only.